.Pharmacolibrary.Drugs.B_BloodAndBloodFormingOrgans.B01A_AntithromboticAgents.B01AC25_Cangrelor.Cangrelor .Pharmacolibrary.Drugs.B_BloodAndBloodFormingOrgans.B01A_AntithromboticAgents.B01AC25_Cangrelor.Cangrelor| name: | Cangrelor |
| ATC code: | B01AC25 | route: | intravenous |
| n-compartments | 2 |
Cangrelor is a potent, reversible, intravenous P2Y12 platelet inhibitor used to prevent thrombotic events in patients undergoing percutaneous coronary intervention (PCI). It is approved for use in adults in the US and EU.
Pharmacokinetic parameters reported in healthy adult volunteers; single and multiple intravenous bolus and infusion dosing.
Motovska, Z, et al., & Group, DS (2024). Cangrelor versus crushed ticagrelor in patients with acute myocardial infarction and cardiogenic shock: rationale and design of the randomised, double-blind DAPT-SHOCK-AMI trial. EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology 20(20) e1309–e1318. DOI:10.4244/EIJ-D-24-00203 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39432252
Fugate, SE, & Cudd, LA (2006). Cangrelor for treatment of coronary thrombosis. The Annals of pharmacotherapy 40(5) 925–930. DOI:10.1345/aph.1G120 PUBMED:https://pubmed.ncbi.nlm.nih.gov/16595568